Introduction: Chronic intestinal pseudoobstruction (CIPO) is a rare, heterogenous, and severe form of gastrointestinal dysmotility. Areas covered: Pertinent literature on pediatric and adult CIPO management has been assessed via PubMed, Scopus, and EMBASE from inception to June 2022. Prokinetics, aimed at restoring intestinal propulsion (e.g. orthopramides and substituted benzamides, acetyl cholinesterase inhibitors, serotonergic agents, and others), have been poorly tested and the available data showed only partial efficacy. Moreover, some prokinetic agents (e.g. orthopramides and substituted benzamides) can cause major side effects. CIPO-related small intestinal bacterial overgrowth requires treatment preferably via poorly absorbable antibiotics to avoid bacterial resistance. Apart from opioids, which worsen gut motility, analgesics should be considered to manage visceral pain, which might dominate the clinical manifestations. Nutritional support, via modified oral feeding, enteral, or parenteral nutrition, is key to halting CIPO-related malnutrition. Expert opinion: There have been significant roadblocks preventing the development of CIPO treatment. Nonetheless, the considerable advancement in neurogastroenterology and pharmacological agents cast hopes to test the actual efficacy of new prokinetics via well-designed clinical trials. Adequate dietary strategies and supplementation remain of crucial importance. Taken together, novel pharmacological and nutritional options are expected to provide adequate treatments forthese patients.

Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction / Di Nardo, Giovanni; Zenzeri, Letizia; Guarino, Matteo; Molfino, Alessio; Parisi, Pasquale; Barbara, Giovanni; Stanghellini, Vincenzo; De Giorgio, Roberto. - In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1747-4124. - 17:4(2023), pp. 1-17. [10.1080/17474124.2023.2193887]

Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction

Di Nardo, Giovanni
Primo
Writing – Review & Editing
;
Zenzeri, Letizia;Molfino, Alessio;Parisi, Pasquale;
2023

Abstract

Introduction: Chronic intestinal pseudoobstruction (CIPO) is a rare, heterogenous, and severe form of gastrointestinal dysmotility. Areas covered: Pertinent literature on pediatric and adult CIPO management has been assessed via PubMed, Scopus, and EMBASE from inception to June 2022. Prokinetics, aimed at restoring intestinal propulsion (e.g. orthopramides and substituted benzamides, acetyl cholinesterase inhibitors, serotonergic agents, and others), have been poorly tested and the available data showed only partial efficacy. Moreover, some prokinetic agents (e.g. orthopramides and substituted benzamides) can cause major side effects. CIPO-related small intestinal bacterial overgrowth requires treatment preferably via poorly absorbable antibiotics to avoid bacterial resistance. Apart from opioids, which worsen gut motility, analgesics should be considered to manage visceral pain, which might dominate the clinical manifestations. Nutritional support, via modified oral feeding, enteral, or parenteral nutrition, is key to halting CIPO-related malnutrition. Expert opinion: There have been significant roadblocks preventing the development of CIPO treatment. Nonetheless, the considerable advancement in neurogastroenterology and pharmacological agents cast hopes to test the actual efficacy of new prokinetics via well-designed clinical trials. Adequate dietary strategies and supplementation remain of crucial importance. Taken together, novel pharmacological and nutritional options are expected to provide adequate treatments forthese patients.
2023
abdominal pain; antibiotics; digestive symptoms; enteral nutrition; parenteral nutrition; prokinetic agents; severe intestinal dysmotility; small intestinal bacterial overgrowth
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction / Di Nardo, Giovanni; Zenzeri, Letizia; Guarino, Matteo; Molfino, Alessio; Parisi, Pasquale; Barbara, Giovanni; Stanghellini, Vincenzo; De Giorgio, Roberto. - In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1747-4124. - 17:4(2023), pp. 1-17. [10.1080/17474124.2023.2193887]
File allegati a questo prodotto
File Dimensione Formato  
DiNardo_Pharmacological-and nutritional-therapy_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1676759
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact